Citations (99)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Aditi Kadakia, Brenna L. Brady, Carole Dembek, G. Rhys Williams & Justine M. Kent. (2022) The incidence and economic burden of extrapyramidal symptoms in patients with schizophrenia treated with second generation antipsychotics in a Medicaid population. Journal of Medical Economics 25:1, pages 87-98.
Read now
Read now
Théo Korchia, Maud Tastevin, Pierre-Louis Sunhary de Verville, Ridha Joober, Christelle Andrieu-Haller, Mélanie Faugere, Ophélia Godin, Damien Etchecopar-Etchart, Fabrice Berna, Bruno Aouizerate, Delphine Capdevielle, Isabelle Chereau, Julie Clauss-Kobayashi, Nathalie Coulon, Jean-Michel Dorey, Caroline Dubertret, Julien Dubreucq, Jasmina Mallet, David Misdrahi, Christine Passerieux, Romain Rey, Frank Schürhoff, Andrei Szoke, Mathieu Urbach, Marion Leboyer, Pierre-Michel Llorca, Christophe Lançon, Raphaelle Richieri, Laurent Boyer & Guillaume Fond. (2022) Precision-medicine findings from the FACE-SZ cohort to develop motivation-enhancing programs in real-world schizophrenia. The World Journal of Biological Psychiatry 23:9, pages 703-714.
Read now
Read now
Amaury Lefebvre, Arnaud Pouchon, Stéphanie Bioulac, Jasmina Mallet, Mircea Polosan & Clément Dondé. (2022) Management of schizophrenia in women during the perinatal period: a synthesis of international recommendations. Expert Opinion on Pharmacotherapy 23:11, pages 1337-1350.
Read now
Read now
Eva Ceskova. (2020) Pharmacological strategies for the management of comorbid depression and schizophrenia. Expert Opinion on Pharmacotherapy 21:4, pages 459-465.
Read now
Read now
Lena Antonsen Stabell, Rolf Gjestad, Rune A. Kroken, Else-Marie Løberg, Hugo A. Jørgensen & Erik Johnsen. (2019) Predictors of treatment satisfaction in antipsychotic-naïve and previously medicated patients with acute-phase psychosis. Nordic Journal of Psychiatry 73:6, pages 349-356.
Read now
Read now
Beth Smith & Steven L. Dubovsky. (2017) Pharmacotherapy of mood disorders and psychosis in pre- and post-natal women. Expert Opinion on Pharmacotherapy 18:16, pages 1703-1719.
Read now
Read now
Alkomiet Hasan, Peter Falkai, Thomas Wobrock, Jeffrey Lieberman, Birte Glenthøj, Wagner F. Gattaz, Florence Thibaut & Hans-Jürgen Möller. (2017) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia – a short version for primary care. International Journal of Psychiatry in Clinical Practice 21:2, pages 82-90.
Read now
Read now
Bettina Lange, Juliane K. Mueller, F. Markus Leweke & J. Malte Bumb. (2017) How gender affects the pharmacotherapeutic approach to treating psychosis – a systematic review. Expert Opinion on Pharmacotherapy 18:4, pages 351-362.
Read now
Read now
Michael Soyka, Henry R. Kranzler, Victor Hesselbrock, Siegfried Kasper, Jochen Mutschler & Hans-Jürgen Möller. (2017) Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. The World Journal of Biological Psychiatry 18:2, pages 86-119.
Read now
Read now
Markus Dold, Magdolna Tardy, Myrto T. Samara, Chunbo Li, Siegfried Kasper & Stefan Leucht. (2016) Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials. The World Journal of Biological Psychiatry 17:3, pages 210-220.
Read now
Read now
Jean-Michel Azorin, Nicolas Simon, Marc Adida & Raoul Belzeaux. (2016) Pharmacological treatment of schizophrenia with comorbid substance use disorder. Expert Opinion on Pharmacotherapy 17:2, pages 231-253.
Read now
Read now
Articles from other publishers (88)
David Misdrahi, Maud Dupuy, Yecodji Dansou, Laurent Boyer, Fabrice Berna, Delphine Capdevielle, Isabelle Chereau, Nathalie Coulon, Thierry D’Amato, Caroline Dubertret, Sylvain Leignier, Pierre Michel Llorca, Christophe Lançon, Jasmina Mallet, Christine Passerieux, Baptiste Pignon, Romain Rey, Franck Schürhoff, Joel Swendsen, Mathieu Urbach, Andrei Szöke, Ophélia Godin, Guillaume Fond, M. Andre, C. Andrieu-Haller, B. Aouizerate, F. Berna, O. Blanc, E. Bourguignon, D. Capdevielle, I. Chereau-Boudet, J. Clauss-Kobayashi, N. Coulon, R. Dassing, J. M. Dorey, C. Dubertret, A. Esselin, G. Fond, F. Gabayet, M. Jarroir, D. Lacelle, M. Leboyer, S. Leignier, P. M. Llorca, J. Mallet, E. Metairie, T. Michel, D. Misdrahi, C. Passerieux, J. Petrucci, B. Pignon, P. Peri, C. Portalier, R. Rey, C. Roman, B. Schorr, F. Schürhoff, A. Szöke, A. Tessier, M. Urbach, G. Wachiche & A. Zinetti-Bertschy. (2023) Predictors of medication adherence in a large 1-year prospective cohort of individuals with schizophrenia: insights from the multicentric FACE-SZ dataset. Translational Psychiatry 13:1.
Crossref
Crossref
Joaquín‐Carlos Martín‐Muñoz, María‐José Acuña, Natividad Carrión‐Mellado, Matilde Blanco‐Venzalá, Laura Mantrana‐Ridruejo, Fernando Rico‐Villademoros, Luisa Rosado‐Tejero & Eva Utrera‐Caballero. (2022) A naturalistic study on the effectiveness of long‐acting antipsychotics in an early intervention program for patients with recent‐onset psychosis. Early Intervention in Psychiatry 17:4, pages 378-384.
Crossref
Crossref
Marco M. Zierhut, Renaldo M. Bernard, Eleanor Turner, Sara Mohamad, Eric Hahn & Malek Bajbouj. (2021) Electroconvulsive therapy for negative symptoms in schizophrenia: a literature review from 2000 to 2021. Current Psychology 42:9, pages 7512-7533.
Crossref
Crossref
Reza Rafizadeh, Marlon Danilewitz, Chad A Bousman, Nickie Mathew, Randall F White, Anees Bahji, William G Honer & Christian G Schütz. (2022) Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: A systematic review and meta-analysis. Journal of Psychopharmacology 37:2, pages 135-143.
Crossref
Crossref
Mishal Qubad & Robert A. Bittner. (2023) Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia. Therapeutic Advances in Psychopharmacology 13, pages 204512532311581.
Crossref
Crossref
Eirik Kjelby, Rolf Gjestad, Farivar Fathian, Igne Sinkeviciute, Renata Alisauskiene, Liss Anda, Else-Marie Løberg, Solveig Klæbo Reitan, Inge Joa, Tor Ketil Larsen, Maria Rettenbacher, Jan Øystein Berle, Ole Bernt Fasmer, Rune Andreas Kroken & Erik Johnsen. (2023) Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders. Journal of Clinical Psychopharmacology Publish Ahead of Print.
Crossref
Crossref
Yoshiyo Oguchi, Atsuo Nakagawa & Hiroki Kocha. (2022) A case of postpsychotic depression improved by switching antipsychotic monotherapy. Neuropsychopharmacology Reports.
Crossref
Crossref
Shangda Li, Renchuan Liu, Bin Sun, Ning Wei, Zhe Shen, Yi Xu & Manli Huang. (2022) Effect of Virtual Reality on Cognitive Impairment and Clinical Symptoms among Patients with Schizophrenia in the Remission Stage: A Randomized Controlled Trial. Brain Sciences 12:11, pages 1572.
Crossref
Crossref
Yuta Yoshino, Hiroshi Kumon, Tetsuya Shimokawa, Hajime Yano, Shinichiro Ochi, Yu Funahashi, Jun-ichi Iga, Seiji Matsuda, Junya Tanaka & Shu-ichi Ueno. (2022) Impact of Gestational Haloperidol Exposure on miR-137-3p and Nr3c1 mRNA Expression in Hippocampus of Offspring Mice. International Journal of Neuropsychopharmacology 25:10, pages 853-862.
Crossref
Crossref
Jill Bjarke, Helga Nødland Gjerde, Hugo Arild Jørgensen, Rune Andreas Kroken, Else-Marie Løberg & Erik Johnsen. (2022) Akathisia and atypical antipsychotics: relation to suicidality, agitation and depression in a clinical trial. Acta Neuropsychiatrica 34:5, pages 282-288.
Crossref
Crossref
Jenny Jung, Eshreena K. Karwal, Steve McDonald, Tari Turner, Doris Chou & Joshua P. Vogel. (2022) Prevention and control of non-communicable diseases in antenatal, intrapartum, and postnatal care: a systematic scoping review of clinical practice guidelines since 2011. BMC Medicine 20:1.
Crossref
Crossref
C. U. Correll, Ofer Agid, Benedicto Crespo-Facorro, Andrea de Bartolomeis, Andrea Fagiolini, Niko Seppälä & Oliver D. Howes. (2022) A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia. CNS Drugs 36:7, pages 659-679.
Crossref
Crossref
Kristýna Vrbová, Ján Praško Pavlov, František Hodný, Marie Ocisková, Jakub Vaněk, Michaela Holubová, Jonáš Boček & Lucie Bundárová. (2022) Schizophrenia and obsessive compulsive disorder. Psychiatrie pro praxi 23:2, pages 64-71.
Crossref
Crossref
Koen Demyttenaere, Elizabeth Anthonis, Károly Acsai & Christoph U. Correll. (2022) Depressive Symptoms and PANSS Symptom Dimensions in Patients With Predominant Negative Symptom Schizophrenia: A Network Analysis. Frontiers in Psychiatry 13.
Crossref
Crossref
Jie Gong, Long‐Biao Cui, Ying‐Song Zhao, Zhao‐Wen Liu, Xue‐Juan Yang, Yi‐Bin Xi, Lin Liu, Peng Liu, Jin‐Bo Sun, Shu‐Wan Zhao, Xiao‐Fan Liu, Jie Jia, Ping Li, Hong Yin & Wei Qin. (2022) The correlation between dynamic functional architecture and response to electroconvulsive therapy combined with antipsychotics in schizophrenia. European Journal of Neuroscience 55:8, pages 2024-2036.
Crossref
Crossref
Bodyl A. Brand, Yudith R. A. Haveman, Franciska de Beer, Janna N. de Boer, Paola Dazzan & Iris E. C. Sommer. (2021) Antipsychotic medication for women with schizophrenia spectrum disorders. Psychological Medicine 52:4, pages 649-663.
Crossref
Crossref
Yuto Yamada, Yusuke Yamauchi, Shinji Sakamoto, Masaki Fujiwara, Yuko Okahisa, Soshi Takao, Manabu Takaki & Norihito Yamada. (2022) Association between depression in chronic phase and future clinical outcome of patients with schizophrenia. Psychopharmacology 239:3, pages 965-975.
Crossref
Crossref
Alison N. Goulding, Torri D. Metz, Jennifer Cook Middleton, M. Camille Hoffman, Emily S. Miller, Tiffany A. Moore Simas, Alison Stuebe, Meera Viswanathan & Bradley N. Gaynes. (2022) Pharmacologic Treatment for Perinatal Mental Health Disorders. Obstetrics & Gynecology 139:2, pages 297-303.
Crossref
Crossref
Yuriy Filts, Robert E. Litman, Javier Martínez, Lourdes Anta, Dieter Naber & Christoph U. Correll. (2022) Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study. Schizophrenia Research 239, pages 83-91.
Crossref
Crossref
Falk Kiefer, Sabine Hoffmann, Julia Arens, Martin Beutel, Oliver Bilke-Hentsch, Gallus Bischof, Udo Bonnet, Jan Malte Bumb, Ralf Demmel, Silke Diestelkamp, Patric Driessen, Isabel Englert, Ursula Fennen, Heribert Fleischmann, Jennis Freyer-Adam, Wilma Funke, Dieter Geyer, Euphrosyne Gouzoulis-Mayfrank, Renate Hannak-Zeltner, Barbara Hansen, Ursula Havemann-Reinecke, Derik Hermann, Eva Hoch, Werner Höhl, Susann Hößelbarth, Kristin Hupfer, Julia Jückstock, Marianne Klein, Andreas Koch, Joachim Köhler, Michael Köhnke, Anne Koopmann, Oliver Kreh, Monika Krönes, Dietmar Kramer, Georg Kremer, Timo Krüger, Nikolaus Lange, Bodo Lieb, Johannes Lindenmeyer, Mathias Luderer, Karl Mann, Peter Missel, Sebastian Mueller, Michael Müller-Mohnssen, Corinna Nels-Lindemann, Tim Neumann, Thomas Polak, Ulrich W. Preuss, Olaf Reis, Gerhard Reymann, Monika Ridinger, Hans-Jürgen Rumpf, Peter-Michael Sack, Ingo Schäfer, Martin Schäfer, Norbert Scherbaum, Ariane Schulte, Welf Schroeder, Manfred Singer, Michael Soyka, Rainer Thomasius, Clemens Veltrup, Monika Vogelgesang, Irmgard Vogt, Marc Walter, Tillmann Weber, Georg Weil, Bernd Wessel, Tina Wessels, Klaudia Winkler, Nadja Wirth, Arnold Wieczorek, Norbert Wodarz & Dirk Wolter. 2022. S3-Leitlinie Screening, Diagnose und Behandlung alkoholbezogener Störungen. S3-Leitlinie Screening, Diagnose und Behandlung alkoholbezogener Störungen
51
356
.
Jelena Vrublevska & Lubova Renemane. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
823
853
.
Ray Alsuhaibani, Douglas Cary Smith, Richard Lowrie, Sumayah Aljhani & Vibhu Paudyal. (2021) Scope, quality and inclusivity of international clinical guidelines on mental health and substance abuse in relation to dual diagnosis, social and community outcomes: a systematic review. BMC Psychiatry 21:1.
Crossref
Crossref
Jurriaan M. J. L. Brouwer, Erien Olde Hengel, Arne J. Risselada, Eric N. van Roon & Hans Mulder. (2021) Applicability of somatic monitoring instructions in clinical practice guidelines on antipsychotic drug use. BMC Psychiatry 21:1.
Crossref
Crossref
Vivien L. Hajak, Göran Hajak, Christoph Ziegelmayer, Simone Grimm & Wolfgang Trapp. (2021) Risk Assessment of Electroconvulsive Therapy in Clinical Routine: A 3-Year Analysis of Life-Threatening Events in More Than 3,000 Treatment Sessions. Frontiers in Psychology 12.
Crossref
Crossref
Cyprien FABRE, Vanessa PAULY, Karine BAUMSTARCK, Damien ETCHECOPAR-ETCHART, Veronica ORLEANS, Pierre-Michel LLORCA, Julie BLANC, Christophe LANCON, Pascal AUQUIER, Laurent BOYER & Guillaume FOND. (2021) Pregnancy, delivery and neonatal complications in women with schizophrenia: a national population-based cohort study. The Lancet Regional Health - Europe 10, pages 100209.
Crossref
Crossref
Meera Viswanathan, Jennifer Cook MiddletonAlison M. StuebeNancy D. BerkmanAlison N. GouldingSkyler McLaurin‐JiangAndrea B. DotsonManny Coker‐SchwimmerClaire BakerChristiane E. VoisinCarla BannBradley N. Gaynes. (2021) Maternal, Fetal, and Child Outcomes of Mental Health Treatments in Women: A Meta‐Analysis of Pharmacotherapy. Psychiatric Research and Clinical Practice 3:3, pages 123-140.
Crossref
Crossref
Nobuatsu Aoki, Taro Suwa, Hirotsugu Kawashima, Aran Tajika, Naotaka Sunada, Toshiyuki Shimizu, Toshiya Murai, Toshihiko Kinoshita & Yoshiteru Takekita. (2021) Sevoflurane in electroconvulsive therapy: A systematic review and meta-analysis of randomised trials. Journal of Psychiatric Research 141, pages 16-25.
Crossref
Crossref
Yasuto Kunii, Junya Matsumoto, Ryuta Izumi, Atsuko Nagaoka, Mizuki Hino, Risa Shishido, Makoto Sainouchi, Hiroyasu Akatsu, Yoshio Hashizume, Akiyoshi Kakita & Hirooki Yabe. (2021) Evidence for Altered Phosphoinositide Signaling-Associated Molecules in the Postmortem Prefrontal Cortex of Patients with Schizophrenia. International Journal of Molecular Sciences 22:15, pages 8280.
Crossref
Crossref
Aline Hajj, Souheil Hallit, Karam Chamoun, Hala Sacre, Sahar Obeid, Chadia Haddad, Sonia Dollfus & Lydia Rabbaa Khabbaz. (2021) Negative symptoms in schizophrenia: correlation with clinical and genetic factors. Pharmacogenomics 22:7, pages 389-399.
Crossref
Crossref
Thomas Hillemacher, Susanne Simen, Marie-Kathrin Rehme & Helge Frieling. (2020) Antipsychotika in der Schwangerschaft: eine systematische ÜbersichtsarbeitAntipsychotics during pregnancy: a systematic review. Der Nervenarzt 92:5, pages 494-500.
Crossref
Crossref
Hitoshi Sakurai, Norio Yasui-Furukori, Takefumi Suzuki, Hiroyuki Uchida, Hajime Baba, Koichiro Watanabe, Ken Inada, Yuka Sugawara Kikuchi, Toshiaki Kikuchi, Asuka Katsuki, Ikuko Kishida & Masaki Kato. (2021) Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus. Pharmacopsychiatry 54:02, pages 60-67.
Crossref
Crossref
Sergey N. Mosolov. (2020) Diagnosis and Treatment of Depression in Patients with Schizophrenia. Consortium Psychiatricum 1:2, pages 29-42.
Crossref
Crossref
Winifred Ekezie, Rachael L Murray, Sanjay Agrawal, Ilze Bogdanovica, John Britton & Jo Leonardi-Bee. (2020) Quality of smoking cessation advice in guidelines of tobacco-related diseases: An updated systematic review. Clinical Medicine 20:6, pages 551-559.
Crossref
Crossref
Friederike Ruppelt, Anja Rohenkohl, Vivien Kraft, Daniel Schöttle, Romy Schröter, Julia Gaianigo, Nathalie Werkle, Anne Daubmann, Anne Karow & Martin Lambert. (2020) Course, remission and recovery in patients with severe psychotic disorders with or without comorbid substance use disorders: Long-term outcome in evidence-based integrated care (ACCESS II study). Schizophrenia Research 222, pages 437-443.
Crossref
Crossref
Syune Hakobyan, Sara Vazirian, Stephen Lee-Cheong, Michael Krausz, William G. Honer & Christian G. Schutz. (2020) Concurrent Disorder Management Guidelines. Systematic Review. Journal of Clinical Medicine 9:8, pages 2406.
Crossref
Crossref
Alkomiet Hasan, Peter Falkai, Isabell Lehmann & Wolfgang Gaebel. (2020) Schizophrenia. Deutsches Ärzteblatt international.
Crossref
Crossref
Alkomiet Hasan, Rupert von Keller, Chris Maria Friemel, Wayne Hall, Miriam Schneider, Dagmar Koethe, F. Markus Leweke, Wolfgang Strube & Eva Hoch. (2019) Cannabis use and psychosis: a review of reviews. European Archives of Psychiatry and Clinical Neuroscience 270:4, pages 403-412.
Crossref
Crossref
J. M. Rubio & J. M. Kane. (2019) How and when to use clozapine. Acta Psychiatrica Scandinavica 141:3, pages 178-189.
Crossref
Crossref
Nestor Szerman, Ignacio Basurte-Villamor, Pablo Vega, Jose Martinez-Raga, Carlos Parro-Torres, Julia Cambra Almerge, Lara Grau-López, Mario De Matteis & Francisco Arias. (2020) Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study. Drugs - Real World Outcomes 7:1, pages 75-83.
Crossref
Crossref
Linnea Stenmark, Katarzyna Popiolek, Robert Bodén, Ole Brus, Åsa Hammar, Mikael Landén, Johan Lundberg, Pia Nordanskog & Axel Nordenskjöld. (2020) Predictors of Treatment Response to Electroconvulsive Therapy in Schizophrenia—A Nationwide Registry-Based Study. Schizophrenia Bulletin Open 1:1.
Crossref
Crossref
Tara Rezapour, Robin L. Aupperle, Martin P. Paulus & Hamed Ekhtiari. 2020. Cognition and Addiction. Cognition and Addiction
393
404
.
Jelena Vrublevska & Lubova Renemane. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
31
.
Mario R. Louzã & Helio Elkis. 2020. Women's Mental Health. Women's Mental Health
49
58
.
Glenn E Hunt, Nandi Siegfried, Kirsten Morley, Carrie Brooke-Sumner & Michelle Cleary. (2019) Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database of Systematic Reviews 2019:12.
Crossref
Crossref
G. Fond, O. Godin, L. Boyer, F. Berna, M. Andrianarisoa, N. Coulon, L. Brunel, E. Bulzacka, B. Aouizerate, D. Capdevielle, I. Chereau, T. D’Amato, C. Dubertret, J. Dubreucq, C. Faget, S. Leignier, C. Lançon, J. Mallet, D. Misdrahi, C. Passerieux, R. Rey, A. Schandrin, M. Urbach, P. Vidailhet, P. M. Llorca, F. Schürhoff & M. Leboyer. (2018) Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort. European Archives of Psychiatry and Clinical Neuroscience 269:8, pages 985-992.
Crossref
Crossref
Jens Reimer, Jens Kuhn, Rita Wietfeld, Wolfgang Janetzky & Karolina Leopold. (2019) „Motivational interviewing“Motivational interviewing. Der Nervenarzt 90:11, pages 1144-1153.
Crossref
Crossref
Julia Martini, Michael Bauer, Ute Lewitzka, Catharina Voss, Andrea Pfennig, Dirk Ritter & Hans-Ulrich Wittchen. (2019) Predictors and outcomes of suicidal ideation during peripartum period. Journal of Affective Disorders 257, pages 518-526.
Crossref
Crossref
Hervé Javelot, Francis Rangoni, Luisa Weiner & Bruno Michel. (2019) High-dose quetiapine and therapeutic monitoring. European Journal of Hospital Pharmacy 26:5, pages 285-287.
Crossref
Crossref
H. Verdoux, E. Pambrun, M. Tournier, S. Cortaredona & P. Verger. (2019) Multi‐trajectories of antidepressant and antipsychotic use: a 11‐year naturalistic study in a community‐based sample. Acta Psychiatrica Scandinavica 139:6, pages 536-547.
Crossref
Crossref
Iris E.C. Sommer, Priscilla P. Oomen & Alkomiet Hasan. (2019) Maintenance treatment for patients with a first psychotic episode. Current Opinion in Psychiatry 32:3, pages 147-156.
Crossref
Crossref
G. Fond, A. Tinland, M. Boucekine, V. Girard, S. Loubière, P. Auquier & L. Boyer. (2019) Prescription of potentially inappropriate psychotropic drugs in homeless people with schizophrenia and bipolar disorders. Results from the French Housing First (FHF) program. Progress in Neuro-Psychopharmacology and Biological Psychiatry 89, pages 84-89.
Crossref
Crossref
Julia Kim, Yusuke Iwata, Eric Plitman, Fernando Caravaggio, Jun Ku Chung, Parita Shah, Daniel M. Blumberger, Bruce G. Pollock, Gary Remington, Ariel Graff-Guerrero & Philip Gerretsen. (2019) A meta-analysis of transcranial direct current stimulation for schizophrenia: “Is more better?”. Journal of Psychiatric Research 110, pages 117-126.
Crossref
Crossref
Hannah K. Betcher, Catalina Montiel & Crystal T. Clark. (2019) Use of Antipsychotic Drugs During Pregnancy. Current Treatment Options in Psychiatry 6:1, pages 17-31.
Crossref
Crossref
M. Na Takuathung, N. Hanprasertpong, S. Teekachunhatean & N. Koonrungsesomboon. (2019)
Impact of
CYP1A2
genetic polymorphisms on pharmacokinetics of antipsychotic drugs: a systematic review and meta-analysis
. Acta Psychiatrica Scandinavica 139:1, pages 15-25.
Crossref
Crossref
Marc Krause, Maximilian Huhn, Johannes Schneider-Thoma, Irene Bighelli, Katharina Gutsmiedl & Stefan Leucht. (2019) Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis. European Neuropsychopharmacology 29:1, pages 32-45.
Crossref
Crossref
. 2019. Therapie psychischer Erkrankungen. Therapie psychischer Erkrankungen
1
119
.
Wolfgang Gaebel, Alkomiet Hasan & Peter Falkai. 2019. S3-Leitlinie Schizophrenie. S3-Leitlinie Schizophrenie
181
254
.
Wolfgang Gaebel, Alkomiet Hasan & Peter Falkai. 2019. S3-Leitlinie Schizophrenie. S3-Leitlinie Schizophrenie
51
137
.
Ana Isabel Cano-Baena, Laura García-Ayala, Marta Zubía-Martín, Iñaki Zorrilla-Martínez & Ana González-Pinto Arrillaga. 2019. Psychopathology in Women. Psychopathology in Women
715
737
.
Per Damkier, Louise Skov Christensen & Anne Broe. (2018) Patterns and predictors for prescription of psychotropics and mood‐stabilizing antiepileptics during pregnancy in Denmark 2000–2016. British Journal of Clinical Pharmacology 84:11, pages 2651-2662.
Crossref
Crossref
Andrew T. Olagunju, Scott R. Clark & Bernhard T. Baune. (2018) Clozapine and Psychosocial Function in Schizophrenia: A Systematic Review and Meta-Analysis. CNS Drugs 32:11, pages 1011-1023.
Crossref
Crossref
C. Dondé, P. Vignaud, E. Poulet, J. Brunelin & F. Haesebaert. (2018) Management of depression in patients with schizophrenia spectrum disorders: a critical review of international guidelines. Acta Psychiatrica Scandinavica 138:4, pages 289-299.
Crossref
Crossref
E. Kjelby, R. Gjestad, I. Sinkeviciute, R.A. Kroken, E.-M. Løberg, H.A. Jørgensen & E. Johnsen. (2018) Trajectories of depressive symptoms in the acute phase of psychosis: Implications for treatment. Journal of Psychiatric Research 103, pages 219-228.
Crossref
Crossref
Per Damkier & Poul Videbech. (2018) The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review. CNS Drugs 32:4, pages 351-366.
Crossref
Crossref
M. Luisa Imaz, Giovanni Oriolo, Mercè Torra, Dolors Soy, Lluïsa García-Esteve & Rocio Martin-Santos. (2018) Clozapine Use During Pregnancy and Lactation: A Case-Series Report. Frontiers in Pharmacology 9.
Crossref
Crossref
Lena Palaniyappan, Priyadharshini Sabesan, Ross Norman & Alkomiet Hasan. 2018. Complex Clinical Conundrums in Psychiatry. Complex Clinical Conundrums in Psychiatry
103
114
.
A. Tinland, K. Zemmour, P. Auquier, M. Boucekine, V. Girard, S. Loubière, G. Fond & Laurent Boyer. (2017) Homeless women with schizophrenia reported lower adherence to their medication than men: results from the French Housing First experience. Social Psychiatry and Psychiatric Epidemiology 52:9, pages 1113-1122.
Crossref
Crossref
Matthias Kirschner, André Aleman & Stefan Kaiser. (2017) Secondary negative symptoms — A review of mechanisms, assessment and treatment. Schizophrenia Research 186, pages 29-38.
Crossref
Crossref
Yasuhiro Gon, Shuichiro Maruoka, Hiroyuki Kishi, Yutaka Kozu, Kuroda Kazumichi, Yasuyuki Nomura, Ikuko Takeshita, Takeshi Oshima & Shu Hashimoto. (2017) NDRG1 is important to maintain the integrity of airway epithelial barrier through claudin-9 expression. Cell Biology International 41:7, pages 716-725.
Crossref
Crossref
Eva Češková, Lenka Sušilová & Libor Ustohal. (2017) Choice of pharmacotherapy in patient s with schizophrenia and co-occurring substance use. Psychiatrie pro praxi 18:1, pages 26-29.
Crossref
Crossref
Noa A Brzezinski-Sinai & Mary V Seeman. (2017) Women and schizophrenia: planning for the future. Future Neurology 12:2, pages 89-99.
Crossref
Crossref
Tom MunyerBrittany Finocchio. 2017. PharmacotherapyFirst: A Multimedia Learning Resource. PharmacotherapyFirst: A Multimedia Learning Resource.
Lucie Bartova & Gabriele Sachs. (2017) Depotbehandlung bei ersterkrankten Patienten mit SchizophrenieDepot Treatment in First-Episode Patients with Schizophrenia. psychopraxis. neuropraxis 20:2, pages 52-59.
Crossref
Crossref
Junya Matsumoto, Hiroki Nakanishi, Yasuto Kunii, Yuki Sugiura, Dai Yuki, Akira Wada, Mizuki Hino, Shin-Ichi Niwa, Takeshi Kondo, Michihiko Waki, Takahiro Hayasaka, Noritaka Masaki, Hiroyasu Akatsu, Yoshio Hashizume, Sakon Yamamoto, Shinji Sato, Takehiko Sasaki, Mitsutoshi Setou & Hirooki Yabe. (2017) Decreased 16:0/20:4-phosphatidylinositol level in the post-mortem prefrontal cortex of elderly patients with schizophrenia. Scientific Reports 7:1.
Crossref
Crossref
Niels Bergemann. 2017. Therapie der Depression. Therapie der Depression
277
308
.
Ulrich Hegerl & Dan Rujescu. 2017. Psychiatrie, Psychosomatik, Psychotherapie. Psychiatrie, Psychosomatik, Psychotherapie
2875
2896
.
Peter Falkai, Rebecca Schennach, Tania Lincoln, Annette Schaub & Alkomiet Hasan. 2017. Psychiatrie, Psychosomatik, Psychotherapie. Psychiatrie, Psychosomatik, Psychotherapie
1583
1674
.
Wolfgang Strube, Beatrice Kirsch, Frank Padberg, Alkomiet Hasan & Ulrich Palm. (2016) Transcranial Direct Current Stimulation as Monotherapy for the Treatment of Auditory Hallucinations During Pregnancy. Journal of Clinical Psychopharmacology 36:5, pages 534-535.
Crossref
Crossref
Cherrie Galletly, David Castle, Frances Dark, Verity Humberstone, Assen Jablensky, Eóin Killackey, Jayashri Kulkarni, Patrick McGorry, Olav Nielssen & Nga Tran. (2016) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Australian & New Zealand Journal of Psychiatry 50:5, pages 410-472.
Crossref
Crossref
Hans-Peter Volz. (2016) Regelbehandlung mit Antipsychotika ist nicht ausreichend effektiv. DNP - Der Neurologe und Psychiater 17:5, pages 31-38.
Crossref
Crossref
Lisa B. Dixon, Yael Holoshitz & Ilana Nossel. (2016) Treatment engagement of individuals experiencing mental illness: review and update. World Psychiatry 15:1, pages 13-20.
Crossref
Crossref
Alkomiet Hasan & Peter Falkai. 2016. Praxishandbuch Schizophrenie. Praxishandbuch Schizophrenie
77
105
.
Claudia Mehler-Wex, Manfred Gerlach & Benno Schimmelmann. 2016. Neuro-/Psychopharmaka im Kindes- und Jugendalter. Neuro-/Psychopharmaka im Kindes- und Jugendalter
187
246
.
Ulrich Hegerl & Dan Rujescu. 2016. Psychiatrie, Psychosomatik, Psychotherapie. Psychiatrie, Psychosomatik, Psychotherapie
1
22
.
Peter Falkai, Rebecca Schennach, Tania Lincoln, Annette Schaub & Alkomiet Hasan. 2016. Psychiatrie, Psychosomatik, Psychotherapie. Psychiatrie, Psychosomatik, Psychotherapie
1
92
.
A. Hasan, T. Wobrock, U. Palm, W. Strube, F. Padberg, P. Falkai, A. Fallgatter & C. Plewnia. (2015) Hirnstimulationsverfahren zur Behandlung schizophrener PsychosenNon-invasive brain stimulation for treatment of schizophrenic psychoses. Der Nervenarzt 86:12, pages 1481-1491.
Crossref
Crossref
Henk Temmingh & Dan J. Stein. (2015) Anxiety in Patients with Schizophrenia: Epidemiology and Management. CNS Drugs 29:10, pages 819-832.
Crossref
Crossref
Alkomiet Hasan, Claus Wolff-Menzler, Sebastian Pfeiffer, Peter Falkai, Elif Weidinger, Andrea Jobst, Imke Hoell, Berend Malchow, Peyman Yeganeh-Doost, Wolfgang Strube, Silke Quast, Norbert Müller & Thomas Wobrock. (2015) Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment of schizophrenia: a bicentric randomized controlled pilot study. European Archives of Psychiatry and Clinical Neuroscience 265:7, pages 589-600.
Crossref
Crossref